This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view

Research pass: thorough Supplement · Capsule OPTIONAL-ADD MEDIUM

Apigenin

Extended Research

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict OPTIONAL-ADD MEDIUM

Strong mechanistic story (CD38/NAD+, GABA, senomorphic) but bioavailability is ~30% with rapid clearance — most users at 50 mg likely under-dose for systemic effects. Cheap insurance bet; would upgrade to STRONG-CANDIDATE if liposomal form used + bloodwork shows estradiol baseline isn't already low.

Research pass: thorough

▸ Decision matrix by user profile Per-archetype

Archetype	Verdict	Rationale
★20-30, brain-priority, high cognitive workload (this-archetype)← your profile	OPTIONAL-ADD	Modest evidence for cognitive benefit in humans. Bioavailability concern means typical doses likely sub-therapeutic for systemic effects (NAD+, senomorphic). Best framed as "NAD+ preservation insurance + chamomile-tier evening calm" — not a primary cognitive driver. Cheap (~$6-30/mo) and low risk → low downside. Aromatase note matters less at 20yo with healthy testosterone production but worth tracking estradiol on June bloodwork. Verdict: optional, prefer liposomal form, won't be felt at 50 mg.
30-50, executive maintenance← your profile	OPTIONAL-ADD	Same logic as above. CD38 climbs with age, so the NAD+ preservation thesis starts to gain traction here. Pair with NAD+ precursor for executives motivated by longevity.
50+, mild cognitive decline / longevity-focus← your profile	STRONG-CANDIDATE	per Sinclair framework. CD38 elevation is more pronounced; NAD+ depletion more measurable; senomorphic effect more clinically meaningful. The longevity-stack thesis hits hardest here. Combine with NMN/NR as the canonical Sinclair pairing.
Anxiety-prone← your profile	OPTIONAL-ADD	Mild anxiolytic via GABA-A — useful as "always-on background" alongside acute tools (theanine, propranolol). Won't replace benzo / SSRI for clinical anxiety.
High athletic load, tested status (WADA-tested)← your profile	OPTIONAL-ADD	Not on any banned list. Low risk. Anti-inflammatory benefit could support recovery.
Sleep-disordered← your profile	OPTIONAL-ADD	Modest sleep aid via GABA-A. Better evidence base for chamomile extract than for isolated apigenin specifically. Stack with magnesium glycinate/threonate + theanine + tryptophan for layered sleep support.
Recovery-focused (post-injury, post-illness)← your profile	OPTIONAL-ADD	Anti-inflammatory + senomorphic story is appealing post-injury but evidence remains preclinical.
Strength/anabolic-focused← your profile	CAUTION	Aromatase inhibition is the lever that bodybuilders sometimes intentionally pull (estrogen control on cycle). Outside that context, dropping endogenous estradiol modestly is anti-anabolic in the long run (E is required for joints, lipids, libido, bone). Risk modest at 50-100 mg/day; meaningful at 200+ mg chronic. Verdict for natural lifters not on cycle: skip or low-dose only.

★20-30, brain-priority, high cognitive workload (this-archetype)
OPTIONAL-ADD
← your profile
Modest evidence for cognitive benefit in humans. Bioavailability concern means typical doses likely sub-therapeutic for systemic effects (NAD+, senomorphic). Best framed as "NAD+ preservation insurance + chamomile-tier evening calm" — not a primary cognitive driver. Cheap (~$6-30/mo) and low risk → low downside. Aromatase note matters less at 20yo with healthy testosterone production but worth tracking estradiol on June bloodwork. Verdict: optional, prefer liposomal form, won't be felt at 50 mg.
30-50, executive maintenance
OPTIONAL-ADD
← your profile
Same logic as above. CD38 climbs with age, so the NAD+ preservation thesis starts to gain traction here. Pair with NAD+ precursor for executives motivated by longevity.
50+, mild cognitive decline / longevity-focus
STRONG-CANDIDATE
← your profile
per Sinclair framework. CD38 elevation is more pronounced; NAD+ depletion more measurable; senomorphic effect more clinically meaningful. The longevity-stack thesis hits hardest here. Combine with NMN/NR as the canonical Sinclair pairing.
Anxiety-prone
OPTIONAL-ADD
← your profile
Mild anxiolytic via GABA-A — useful as "always-on background" alongside acute tools (theanine, propranolol). Won't replace benzo / SSRI for clinical anxiety.
High athletic load, tested status (WADA-tested)
OPTIONAL-ADD
← your profile
Not on any banned list. Low risk. Anti-inflammatory benefit could support recovery.
Sleep-disordered
OPTIONAL-ADD
← your profile
Modest sleep aid via GABA-A. Better evidence base for chamomile *extract* than for isolated apigenin specifically. Stack with magnesium glycinate/threonate + theanine + tryptophan for layered sleep support.
Recovery-focused (post-injury, post-illness)
OPTIONAL-ADD
← your profile
Anti-inflammatory + senomorphic story is appealing post-injury but evidence remains preclinical.
Strength/anabolic-focused
CAUTION
← your profile
Aromatase inhibition is the lever that bodybuilders sometimes intentionally pull (estrogen control on cycle). Outside that context, dropping endogenous estradiol modestly is anti-anabolic in the long run (E is required for joints, lipids, libido, bone). Risk modest at 50-100 mg/day; meaningful at 200+ mg chronic. Verdict for natural lifters not on cycle: skip or low-dose only.

▸ Subjective experience (deep)

Most users at 50 mg report nothing noticeable. This is consistent with the bioavailability problem and the mild GABA-A binding affinity.

At 200 mg+ (or with liposomal 50-100 mg), reports cluster around:

Mild calm / "background quiet" 30-90 minutes after dose
Slight drowsiness if taken evening (the basis for the Huberman pre-bed protocol)
Easier sleep onset for some, especially when stacked with magnesium + theanine
Vivid dreams occasionally reported
No stimulant-like or pro-cognitive felt effect — anyone reporting a sharp "nootropic" boost at dietary doses is likely placebo

Onset: 30 min – 2.5 hr (Tmax). Half-life: ~2.5 hr → effect wanes within 4-6 hr.

▸ Tolerance + cycling deep dive

Tolerance buildup: Minimal / unknown. No tolerance signal in any chronic-dosing study. CD38 enzyme inhibition is not classically downregulating. GABA-A binding is weak enough that benzodiazepine-style tolerance is not expected at supplemental doses.
Recommended cycle: Daily, no cycling needed. Encyclopedia agrees.
Reset protocol if needed: Not applicable. If estradiol drops too low, discontinue and recheck in 4-6 weeks.

▸ Stacking deep dive

Synergistic with

nad-plus precursors (NMN, NR): The complementary thesis — apigenin slows NAD+ destruction (CD38 inhibition) while NMN/NR raise NAD+ supply. Sinclair-lab framework explicitly endorses this combo.
taurine: Both are GABA-A positive modulators with weak affinity → mild additive calm without sedation. Both anti-excitotoxic, theoretically helpful for impact recovery (MMA).
l-tryptophan: Pre-bed sleep stack. Tryptophan → serotonin → melatonin while apigenin contributes mild GABA-A tone. Logical the canonical stack: apigenin + tryptophan + magnesium glycinate/threonate evening.
astaxanthin: Both lipid-soluble antioxidants; complementary anti-inflammatory pathways (apigenin = NLRP3, astaxanthin = mitochondrial ROS scavenging).
foxo4-dri (theoretical): FOXO4-DRI is a classical senolytic; apigenin is senomorphic. Conceptually you'd run senolytic in pulses + senomorphic chronically. No human data on combining, purely theoretical.
curcumin (already V4): Both anti-inflammatory, both flavonoid-class, no interaction concern, reinforcing.
theanine: GABA modulation + glutamate modulation pair well for evening calm.

Avoid stacking with

Pharmaceutical aromatase inhibitors (anastrozole, letrozole, exemestane) — additive estradiol suppression. Not relevant for users in this archetype but flag for anyone on AI therapy.
Other strong aromatase-inhibiting flavonoids (chrysin high-dose, some grape-skin extracts) — same additive concern.
CYP3A4-substrate drugs at narrow therapeutic index (see Drug interactions). Not a stacking issue per se but worth flagging.
Tamoxifen / SERMs: Apigenin's biphasic ER activity could interfere; oncology patients on these drugs should consult oncologist.

Neutral / safe co-administration

Modafinil (no known interaction; mechanism non-overlapping)
Bromantane, Semax, Selank, Adamax (no overlap)
Cerebrolysin (complementary neuroprotection)
All V4 components: NAC, citicoline, magnesium, fish oil, PS, rhodiola, theanine, glycine, vitamin D, beta-alanine, vitamin C, creatine — no concerns.
Caffeine (no interaction; opposing wake/calm not pharmacological)

▸ Drug interactions deep dive

Apigenin inhibits multiple CYP enzymes — human in-vivo significance is debated because oral bioavailability is poor, but the inhibition is real and matters for high-dose users or those on narrow-therapeutic-index drugs.

CYP3A4: Reversible inhibition, reported IC50 ~0.4 µM. Clinically modest. Drugs to watch: many statins (simvastatin, atorvastatin), some calcium channel blockers, midazolam, alfentanil, immunosuppressants (cyclosporine, tacrolimus), some cancer drugs (imatinib — apigenin shown to increase imatinib AUC in rats).
CYP2C9: Inhibition reported. Drugs to watch: warfarin (bleeding risk), NSAIDs, fluvastatin, sulfonylureas, irbesartan, losartan.
CYP1A2: Inhibition reported. Drugs to watch: caffeine (could mildly raise caffeine levels — the user's caffeine ramp is relevant), theophylline, clozapine, olanzapine.
P-glycoprotein: Some inhibition; relevant for digoxin, some chemo drugs.
Hormonal drugs: Combined OCPs / HRT — theoretical interaction via aromatase + ER pathways. Monitor.
Anticoagulants/antiplatelets: Theoretical mild bleeding risk via platelet pathways + CYP2C9/warfarin. Monitor INR if relevant.

For the user: not on any of these drugs. The caffeine + apigenin combination is mild — apigenin's CYP1A2 inhibition could nudge caffeine half-life slightly upward, possibly amplifying his caffeine ramp slightly. Negligible at 50 mg apigenin pre-bed (caffeine should already be cleared by then).

▸ Pharmacogenomics

CYP3A4/CYP3A5 polymorphisms: Carriers of CYP3A5 *3 (poor expressers — common in white populations including Nordic ancestry) already have lower CYP3A activity; adding apigenin compounds the inhibition. Practical effect: more cumulative drug exposure for any CYP3A4 substrate co-administered.
**CYP2C9 2/3 carriers (slow metabolizers): Higher exposure/effect for CYP2C9 substrates when combined with apigenin. Relevant if the user ever takes warfarin or NSAIDs chronically.
*CYP1A2 1F (rapid inducer phenotype, common in white/Nordic): Faster baseline caffeine clearance — apigenin's mild CYP1A2 inhibition could partially counteract this.
COMT Val158Met: No direct apigenin interaction, but Val/Val (slow methylators) might subjectively feel apigenin's calming effect more clearly given baseline higher dopamine/norepinephrine.
Once 23andMe results land (~June 2026): check CYP3A5, CYP1A2, CYP2C9 status for users in this archetype. If poor metabolizer phenotype, consider lower apigenin dose or split dosing.

▸ Sourcing deep dive

Path	Vendor	Cost	Reliability	Notes
OTC supplement	Nootropics Depot — 50 mg ×180 caps OR 200 mg ×120 caps	~$20-40/bottle, ~$8-15/mo at 50 mg/day	high	98%+ purity, third-party tested. Standard powder, not liposomal. Encyclopedia top pick.
OTC supplement	Toniiq Liposomal Apigenin — 100 mg ×180 caps	$29.97 ($25.47 sub) → ~$15-30/mo	high	Liposomal — solves the bioavailability problem. At 50 mg/day = ~$15/mo. Best form-factor pick.
OTC supplement	Double Wood Apigenin — 50 mg ×120 caps	$24.95/bottle = ~$6/mo at 50 mg/day	medium-high	Cheapest reputable option. Standard powder, no liposomal.
OTC supplement	Pure Bulk apigenin powder	~$10-20 / 5-10g, ~$3-8/mo	medium	Cheap bulk powder; weigh own doses. No liposomal.
OTC supplement	iHerb — various brands	varies, ~$10-20/mo	medium	Easy add to existing iHerb V4 cart. Verify purity claims.
Phytosome	APLC (research-grade) — limited consumer products	varies	medium	36× solubility increase vs base apigenin (Telang 2016). Few consumer SKUs.

Recommendation for users in this archetype: Toniiq Liposomal 100 mg every other day OR daily (~~$15-30/mo). If price-sensitive, Double Wood 50 mg standard powder (~~$6/mo) but accept under-dosing for systemic effects (still gets some GABA-A action since brain delivery is local-receptor not systemic-AUC dependent).

▸ Biomarkers to track (deep)

Baseline (before starting):
- Total + free testosterone
- Estradiol (sensitive assay — LC-MS/MS preferred for men, range 10-40 pg/mL)
- SHBG
- hs-CRP, IL-6 (inflammation baseline)
- Liver panel (ALT, AST, ALP)
- For longevity pass: NAD+ if testable (Jinfiniti or similar)
During use: Re-check estradiol + testosterone at 12 weeks if dosing ≥100 mg/day. Liver panel if any GI symptoms or jaundice (precaution; clinical risk minimal).
Subjective (cheap, daily): Sleep quality (PSQI weekly or Oura/Whoop trend), libido, morning erection frequency, joint comfort, mood (GAD-7 monthly).
Post-cycle: N/A — daily dosing protocol.

▸ Controversies / open debates Live debate

Sinclair lab's CD38/apigenin thesis vs. translational reality: The 2013 paper showed mouse hepatic NAD+ doubled with IP apigenin. Oral apigenin's poor bioavailability means most humans at 50-200 mg oral may not reach the tissue concentrations needed. No human NAD+ data exists for oral apigenin specifically. The longevity claim rests on solid mechanism + animal evidence + zero human verification.
Senolytic vs. senomorphic confusion: Older literature (and many supplement marketers) call apigenin "senolytic." 2024-2025 work clarifies it's senomorphic — suppresses SASP rather than killing senescent cells. This matters because senolytics are dosed in pulses (FOXO4-DRI, dasatinib + quercetin) while senomorphics are dosed chronically. Consumer messaging hasn't caught up.
"50 mg human attention study" claim: The the user encyclopedia and several supplement vendors cite a 50 mg human study showing attention/concentration improvement. I cannot verify a published, peer-reviewed clinical trial of isolated apigenin at 50 mg for cognition. A 2024 systematic review (PMC10813036) explicitly states no clinical trials test apigenin for cognitive aging. This may be a mis-citation propagated from a chamomile-extract study or a low-quality unblinded vendor trial. Flag for accuracy review.
Aromatase concern in healthy young men: No human RCT measures estradiol changes in healthy young men taking apigenin chronically. Concern is mechanistic (in vitro IC50 ~2.9 µM) extrapolation. Real-world risk at 50 mg likely small but non-zero.
Bioavailability claims vs. consumer reality: Vendors selling standard powdered apigenin imply equivalent benefit to liposomal forms — pharmacokinetic studies show 3-4× AUC differences. Most users at 50 mg standard powder are likely in the "barely measurable in plasma" zone for systemic effects, even if local GABA-A tone in CNS is reachable.
Clinical-trial gap: Despite ~30 years of preclinical work, isolated apigenin has minimal human trial coverage. Chamomile extract data is the practical bridge but doesn't isolate apigenin's contribution.

▸ Verdict change log

2026-05-05 — Initial verdict: OPTIONAL-ADD, MEDIUM confidence. Mechanism story strong, human evidence thin, bioavailability is the dominant problem. Recommend liposomal form (Toniiq) over standard 50 mg powder if a user in this archetype wants a real shot at systemic CD38/NAD+ effects. Risk profile clean enough that even minimal benefit justifies the $6-30/mo cost.

▸ Open questions / gaps Open

No human PK/PD study at supplemental doses with NAD+ measurement. The whole longevity thesis hinges on NAD+ preservation that has only been measured in mouse liver after IP injection. A 12-week human RCT measuring serum/intracellular NAD+ with oral 50/100/200 mg apigenin — standard vs. liposomal — would settle the basic question.
No human estradiol-impact study in young healthy men. Chronic 100-200 mg apigenin × 12 weeks measuring estradiol/testosterone/SHBG would close the safety gap for athletes/bodybuilders.
No human cognitive RCT. The "50 mg attention study" cited in the encyclopedia needs verification; if it doesn't exist, that line should be corrected.
Liposomal apigenin pricing/quality landscape is shallow. Toniiq is the main consumer SKU; would benefit from second/third reputable competitor (Quicksilver, Designs for Health, etc. don't currently carry it).
CD38 inhibitor combinatorial therapy: No data on apigenin + NMN vs. either alone in humans. The Sinclair-lab logic strongly suggests synergy but it's untested.
Quercetin/EGCG family overlap: Apigenin overlaps mechanistically with quercetin (also CD38 inhibitor + senolytic-adjacent) and EGCG (anti-inflammatory + CYP inhibitor). Stacking three flavonoids that all inhibit CYP3A4/CYP2C9 amplifies drug-interaction risk. Open question whether running apigenin + quercetin + EGCG provides more benefit than any one alone.

Loading…

Apigenin

Our depth — beyond the mirror

Synergistic with

Avoid stacking with

Neutral / safe co-administration

References

Escande et al., 2013 — Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38 (Sinclair lab co-author)

Zhang et al., 2025 — Targeting Senescence with Apigenin Improves Chemotherapeutic Efficacy and Ameliorates Age-Related Conditions in Mice (Advanced Science)

Salmani et al. — Apigenin: a component of Matricaria recutita is a central benzodiazepine receptor ligand with anxiolytic effects

Telang et al., 2016 — Apigenin-phospholipid phytosome (APLC) for improved bioavailability

Self-nanoemulsifying drug delivery systems for apigenin (Scientific Reports, 2024)

Recent advancement in delivery systems of apigenin (PMC, 2023)

Apigenin unveiled: encyclopedic preclinical and clinical review (Discover Plants, 2024)

Beneficial Role of Apigenin against Cognitive Dysfunction: Systematic Review (PMC, 2024)

Characterization of CYP3A4 Inhibition Potential of Selected Flavonoids (PMC)

CD38 inhibition by apigenin ameliorates mitochondrial oxidative stress in diabetic rats (PMC)

Apigenin improves testosterone synthesis by regulating ER stress (2024)

Sinclair Lab Publications

Apigenin: a natural molecule at the intersection of sleep and aging (Frontiers Nutrition, 2024)

Repurposing the plant-derived compound apigenin for senomorphic effect (bioRxiv, 2024)

Apigenin inhibits NLRP3 inflammasome activation (Frontiers Immunology, 2024)

Pharmacokinetic properties and drug interactions of apigenin (Expert Opinion Drug Metab Toxicol)

Examine.com — Apigenin

AlzDiscovery Cognitive Vitality — Apigenin researcher report

Huberman 50 mg pre-bed sleep stack (FastLifeHacks summary)

Toniiq Liposomal Apigenin product page

Nootropics Depot Apigenin Capsules

Double Wood Apigenin product page

Apigenin: Benefits and Side Effects (Lifespan Research Institute)

How was your experience with this compound?

See something off?

Educational research only.
Not medical advice.